Drugs / DVS-SR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00277823 | Feb 2006 → Jan 2007 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DVS-SR | “Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder” NCT00277823 ↗ |
| Known as | DVS-SR 50 mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00277823 ↗ |